Repligen FY2026 EPS Forecast Decreased by Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2026 EPS forecast for Repligen, lowering it from $2.18 to $2.13 per share.
• Repligen's recent quarterly earnings report showed a miss in EPS at $0.37, compared to analysts' expectations of $0.40, while revenue increased by 14.8% year-over-year to $182.37 million.
• Multiple investment firms have adjusted their price targets for Repligen, with Canaccord Genuity lowering their target to $150.00 and Wells Fargo reducing theirs to $175.00, indicating a mixed outlook for the stock.

Repligen Corporation (NASDAQ:RGEN - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2026 EPS estimates for shares of Repligen in a note issued to investors on Tuesday, July 29th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will earn $2.13 per share for the year, down from their prior estimate of $2.18. The consensus estimate for Repligen's current full-year earnings is $1.72 per share.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period last year, the company posted $0.40 EPS. The business's revenue was up 14.8% on a year-over-year basis.

RGEN has been the subject of several other reports. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Finally, Wells Fargo & Company decreased their price objective on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $169.45.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $117.07 on Friday. The company has a market cap of $6.58 billion, a price-to-earnings ratio of -468.26, a PEG ratio of 2.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. The firm has a 50 day simple moving average of $123.46 and a 200 day simple moving average of $136.78. Repligen has a one year low of $102.96 and a one year high of $182.52.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale grew its stake in Repligen by 1.0% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company's stock valued at $961,000 after acquiring an additional 80 shares in the last quarter. Alliance Wealth Advisors LLC UT grew its stake in Repligen by 2.5% during the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after acquiring an additional 89 shares in the last quarter. Drive Wealth Management LLC grew its stake in Repligen by 2.5% during the second quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company's stock valued at $472,000 after acquiring an additional 93 shares in the last quarter. Utah Retirement Systems grew its stake in Repligen by 1.1% during the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 100 shares in the last quarter. Finally, State of Michigan Retirement System grew its stake in Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after acquiring an additional 100 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.